Tempest Therapeutics, Inc. (TPST)
| Market Cap | 5.96M -85.9% |
| Revenue (ttm) | n/a |
| Net Income | -40.47M |
| EPS | -4.56 |
| Shares Out | 16.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,217 |
| Open | 0.3971 |
| Previous Close | 0.3614 |
| Day's Range | 0.3600 - 0.3997 |
| 52-Week Range | 0.3600 - 10.3290 |
| Beta | -1.56 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About TPST
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr... [Read more]
Financial Performance
Financial StatementsNews
Tempest Therapeutics Transcript: AGM 2026
A quorum of 50.7% of voting power was represented. Stockholders approved all four proposals, including two director nominees, auditor ratification, and the proposed equity issuances.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on October 20, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics Transcript: AGM 2026
Proxies representing 74.3% of outstanding shares established a quorum, but Proposal One lacked sufficient support. The meeting was adjourned to November 12, 2026, for further stockholder consideration.
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset d...
Tempest Therapeutics files to sell 9.53M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 9.53M shares of common stock. The company is not selling any…
Tempest Therapeutics Registration statement: Registration filing
Tempest Therapeutics filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
Tempest Therapeutics price target lowered to $7 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Tempest Therapeutics (TPST) to $7 from $11 and keeps a Buy rating on the shares. Tempest provided several recent…
Tempest Therapeutics appoints Freda-Smith to board of directors
Tempest Therapeutics (TPST) announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset ...
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on September 16, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
-Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
Tempest Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A clinical-stage in vivo CAR-T platform is advancing dual-targeting therapies for cancer and autoimmune diseases, showing strong early efficacy and safety in relapsed multiple myeloma and rare disease patients. New partnerships and rapid development plans position the company as a leader in this emerging field.
Tempest Therapeutics Slides: Corporate presentation
Tempest Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Tempest Therapeutics announces $7.5M private placement
Tempest Therapeutics (TPST) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock, series C warrants to purchase…
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potenti...
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T ...
Tempest Therapeutics files to sell 8.91M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 8.91M shares of common stock. The company is not selling any…
Tempest Therapeutics Registration statement: Registration filing
Tempest Therapeutics filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patie...
Tempest Therapeutics Earnings release: Q2 2026
Tempest Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Tempest Therapeutics Quarterly report: Q2 2026
Tempest Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.